Hilary McLauchlan
Papers
1
Total Citations
49
H-Index
1
About
Hilary McLauchlan is a leading researcher in chemical biology and drug discovery, with a primary focus on the ubiquitin-proteasome system and deubiquitylating enzymes (DUBs). Her major contributions center on developing innovative, high-throughput screening methodologies to identify small-molecule modulators of DUBs, which are critical targets for cancer and neurodegenerative disease therapies. Her most cited work, a 2020 study on a high-throughput MALDI-TOF mass spectrometry–based DUB assay, has garnered 49 citations and represents a paradigm shift in drug discovery by enabling rapid, label-free, and sensitive detection of enzyme activity. This assay has become a cornerstone for academic and pharmaceutical researchers seeking to accelerate the development of DUB inhibitors. McLauchlan’s research bridges the gap between fundamental enzymology and translational medicine, providing tools that directly impact the drug development pipeline. Her work is notable for its technical rigor and practical applicability, empowering scientists to explore previously intractable targets. With a growing citation record and a reputation for method innovation, McLauchlan is a key figure in the quest to harness the ubiquitin system for therapeutic benefit.
Research Focus
Key Achievements
Top Papers
- 1